Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trivalent nOPV (nOPV1+2+3) safety and immunogenicity
NCT06137664Phase 2Recruiting
- Sponsor
- PATH
- Start
- Nov 2024
- Primary completion
- Dec 2027
- Modality
- Live Attenuated Vaccines, Live Biotherapeutic Products
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of Novel oral polio vaccine type 1, nOPV2 and novel oral polio vaccine type 3 in poliomyelitis (14 arms), sponsored by PATH. Primary endpoints: Serious Adverse Events at 197 days, Solicited Adverse Events at 7 days and 3 more. Started Nov 2024; status: recruiting.
02
Drugs
Novel oral polio vaccine type 1nOPV2novel oral polio vaccine type 3
03
Conditions
poliomyelitis
Beyond the preview
Go deeper on NCT06137664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06137664.